Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArdelyxARDX -1.95%70 EV-to-EBIT is -42.02 as of Jul. 26, 2026. GuruFocus rates ARDX with a GF Score™ of 70/100 and a GF Value™ of $10.39 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 378 Biotechnology companies, Ardelyx ranks worse than 264550% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ardelyx's Enterprise Value is $1,214.0 Mil.
Ardelyx's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-28.9 Mil. Therefore, Ardelyx's EV-to-EBIT for today is -42.02.
The historical rank and industry rank for Ardelyx's EV-to-EBIT or its related term are showing as below:
ARDX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -71.3 Med: -4.86 Max: 0.68
Current: -42.02
During the past 13 years, the highest EV-to-EBIT of Ardelyx was 0.68. The lowest was -71.30. And the median was -4.86.
ARDX's EV-to-EBIT is ranked worse than 100% of 378
companies
in the Biotechnology industry
Industry Median: 12.775
vs ARDX: -42.02
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ardelyx's Enterprise Value for the quarter that ended in Mar. 2026 was $1,449.6 Mil.
Ardelyx's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx EV-to-EBIT Related Terms
Ardelyx EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ardelyx's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ardelyx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ardelyx's EV-to-EBIT falls into.
Ardelyx's current Enterprise Value is $1,214.0 Mil.
Ardelyx's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx (ARDX) has a EV-to-EBIT of -42.02 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ardelyx and its competitors. According to the industry distribution chart, Ardelyx ranks #999999 out of 378 companies in the Biotechnology industry.
Is Ardelyx's EV-to-EBIT too high?
Ardelyx's current EV-to-EBIT is -42.02. Based on the distribution chart, Ardelyx ranks #999999 out of 378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ardelyx has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's EV-to-EBIT compare to AVLN and INBX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #999999 out of 378 companies for EV-to-EBIT. This places Ardelyx in the lower half of its industry. The industry median EV-to-EBIT is 12.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.78, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ardelyx and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ardelyx's current EV-to-EBIT is -42.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is $10.39, compared to a current price of $5.04 — trading 51.5% below its estimated fair value. The current EV-to-EBIT is -42.02. Ardelyx's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ardelyx (ARDX), the current EV-to-EBIT is -42.02 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of $5.04 is trading 51.5% below its estimated GF Value™ of $10.39.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for ARDX:
EV-to-EBIT: -42.02
GF Value™: $10.39 vs. price of $5.04 (51.5% below fair value)
No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
70GF Score
Get the complete analysis for ARDX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARDX has been successfully added to your 
